Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia.
about
Human immunodeficiency virus infection and pneumothoraxOutcome of HIV-associated Pneumocystis pneumonia in hospitalized patients from 2000 through 2003.Newly formed cystic lesions for the development of pneumomediastinum in Pneumocystis jirovecii pneumonia.Downregulation of PU.1 leads to decreased expression of Dectin-1 in alveolar macrophages during Pneumocystis pneumonia.Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unitMortality of patients infected with HIV in the intensive care unit (2005 through 2010): significant role of chronic hepatitis C and severe sepsis.Toll-like receptor 2 mediates alveolar macrophage response to Pneumocystis murinaCharacteristics and outcomes of HIV-1-infected patients with acute respiratory distress syndromeIL-33 and M2a alveolar macrophages promote lung defense against the atypical fungal pathogen Pneumocystis murina.Critical illness in HIV-infected patients in the era of combination antiretroviral therapy.Imported acquired immunodeficiency syndrome-related histoplasmosis in metropolitan France: a comparison of pre-highly active anti-retroviral therapy and highly active anti-retroviral therapy erasManagement of Pneumocystis Jirovecii pneumonia in HIV infected patients: current options, challenges and future directions.Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance.Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections.Colonization by Pneumocystis jirovecii and its role in disease.Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia: the "red complex", a prototype polybacterial pathogenic consortium in periodontitis.Short-term mortality and implementation of antiretroviral treatment for critically ill HIV-infected children in a developing country.Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapySurvival of HIV-infected patients in the intensive care unit in the era of highly active antiretroviral therapy.Short- and long-term outcomes of HIV-infected patients admitted to the intensive care unit: impact of antiretroviral therapy and immunovirological status.Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the Dectin-1 beta-glucan receptor.Decreased inflammatory response in Toll-like receptor 2 knockout mice is associated with exacerbated Pneumocystis pneumoniaLife-threatening complications of HIV infection.Clinical and translational research in pneumocystis and pneumocystis pneumonia.Current understanding of Pneumocystis immunology.Clinical review: Respiratory failure in HIV-infected patients--a changing picture.Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006.Respiratory infection complicating HIV infectionLow tidal volume ventilation is associated with reduced mortality in HIV-infected patients with acute lung injury.The absence of Hck, Fgr, and Lyn tyrosine kinases augments lung innate immune responses to Pneumocystis murina.Survival for patients With HIV admitted to the ICU continues to improve in the current era of combination antiretroviral therapy.Predicting mortality from HIV-associated Pneumocystis pneumonia at illness presentation: an observational cohort studyGood outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients.An official ATS workshop report: Emerging issues and current controversies in HIV-associated pulmonary diseases.The changing epidemiology of HIV-infected patients in the intensive care unit.When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now!The long-term outcome of HIV-infected patients after intensive care admission.Classical versus alternative macrophage activation: the Ying and the Yang in host defense against pulmonary fungal infections.Provision of critical care services to HIV-infected children in an era of advanced intensive care and availability of combined antiretroviral therapy.Detection of a proteasome in Pneumocystis carinii and its modulation by specific proteasome inhibitors.
P2860
Q26991924-DB677198-DBDC-48CB-93EA-E29750F0775FQ33369974-5FEAF43B-0AA7-4E93-B5B5-62EF5507875AQ33511054-38BECCBF-FE9D-466B-94F6-AAC8FCCB937AQ33676073-679F2D87-57E6-49D3-8F6D-19172CCE0517Q34086264-991A2626-1F78-44C1-A0F6-9671BFC73147Q34250648-05BA301E-B6DF-417E-91A3-514787DB0F92Q34491774-D5BC008A-3800-4DD5-A48C-4F9184A75211Q34718171-9B906E71-449F-42E0-AE95-FA85E0FA0365Q34762141-A6060870-55AF-4372-84BB-5200B1E8FFE6Q35095045-892BDF54-7A1D-4D33-B60B-024F2DF43322Q35494596-FF377DA8-3386-4ED5-BD73-2D861FB5E6E8Q35557252-BD26EC84-2CEA-4634-8D34-E02D936254FAQ35880756-0DF90095-9A5A-4D0A-ADDD-5737D53A3D1BQ35905025-7D60E047-B351-491E-A6B2-63DF403DD901Q35940586-AC559B35-F2EE-4B19-88C1-37AF5B3F0F86Q36107786-379FA2F2-540C-4374-B8E1-21CCDE7CE53EQ36154492-3AF686F9-9C32-4FC7-9B2E-72518B2DD1CCQ36184151-103D4991-73FD-4295-8013-CFA114C6B1A9Q36225459-79ADD393-F7F4-44EF-A54F-0D6D1627EF0FQ36300347-0BA0EA13-2509-4F9C-8624-10CE6C5D1AD2Q36371523-298BA582-09F9-4F83-BF71-21B6A2051A79Q36711650-7465EEB4-483B-4F8C-B898-68ABE09315D5Q36800706-22C55662-81FB-42A5-9797-52E8E56F9A6BQ36899081-78F9107C-3051-4DBE-B175-25025D7C8F84Q36984703-89867990-5E42-4074-A2FA-9E0BDF3AB59FQ36998358-F657F6AD-82EB-4F68-A4B3-845F76647F3BQ37055188-A5AADB4B-7C2A-4BEA-8BDA-003CB8C3553AQ37085842-CBF2246E-8B05-4FF8-810C-9EFD8752EAD8Q37179389-D78B29A9-F735-429C-9ABB-6134D12FB543Q37191294-13DEEA17-6044-44CA-899E-EE21EB92EA15Q37342714-8A668411-9B43-4820-94B8-D47507BAA522Q37457246-96DBA076-7901-41C8-8F55-D3E7D920844DQ37634515-9693D6A5-BBB6-41E6-8255-1F1C050B87F4Q37848593-A4A6AF18-98C7-4562-872E-62181B71390DQ37857545-5B55BD5F-E6E5-4362-BFC3-0F37E7806E87Q38021725-A9136D7A-335B-4D7C-995A-3F1FB2984B40Q38027139-8548772E-7A44-4025-B391-E69F709DC7BDQ38235148-4321060B-9A0E-4A5A-B5A3-B6CBA70A19E8Q39115804-765A9A1A-521F-4BC6-82AC-2EA759117656Q40196579-77CBEB72-7A3C-4BED-8102-57EDB82CAF9B
P2860
Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Improved survival with highly ...... neumocystis carinii pneumonia.
@ast
Improved survival with highly ...... neumocystis carinii pneumonia.
@en
type
label
Improved survival with highly ...... neumocystis carinii pneumonia.
@ast
Improved survival with highly ...... neumocystis carinii pneumonia.
@en
prefLabel
Improved survival with highly ...... neumocystis carinii pneumonia.
@ast
Improved survival with highly ...... neumocystis carinii pneumonia.
@en
P2093
P1433
P1476
Improved survival with highly ...... neumocystis carinii pneumonia.
@en
P2093
Alison Morris
Joan Turner
Laurence Huang
Robert M Wachter
P356
10.1097/00002030-200301030-00010
P407
P577
2003-01-01T00:00:00Z